시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 바이오마커 탐색 아웃소싱 서비스 시장 보고서(2025년)
Biomarker Discovery Outsourcing Services Global Market Report 2025
상품코드 : 1825634
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

바이오마커 탐색 아웃소싱 서비스 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 CAGR은 15.4%를 나타낼 것으로 예측되고 301억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 맞춤형 의약품 확대, 인공지능(AI) 및 머신 러닝 통합, 정밀 종양학 성장, 바이오마커 검증 서비스, 규제 지원, 표적 치료 수요, 환자 중심 의료 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 정밀의학 채택 증가, 기술적 발전, 동반진단 수요 증가, 신약 개발 파이프라인 확대, 비전통적 질환 영역에서의 신흥 용도, 인공지능(AI) 및 머신 러닝(ML) 통합, 규제 지원 및 표준화, 전 세계 시장 확장, 파트너십 및 협력, 비용 효율성과 시간 효율성에 대한 주력 등이 포함됩니다.

향후 5년간 15.4% 성장률 전망은 해당 시장에 대한 이전 추정치 대비 0.5% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 부과로 스웨덴 및 덴마크에서 수입되는 프로테오믹스 분석 및 멀티오믹스 플랫폼 접근이 제한되어 미국 정밀의학 분야에 상당한 도전이 될 수 있으며, 이는 바이오마커 식별 속도 저하 및 연구 비용 증가로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 나타날 것입니다.

맞춤형 의약품에 대한 강조가 증가함에 따라 바이오마커 탐색 아웃소싱 서비스 시장 성장이 촉진될 전망입니다. 맞춤형 의약품은 유전적, 생활습관적, 환경적 요인을 고려하여 각 환자의 개별 특성에 맞춘 의료 처방을 통해 정밀한 의료 결과를 도출하고 부작용을 감축합니다. 바이오마커 탐색 서비스 아웃소싱은 환자의 고유한 생물학적 표지자를 기반으로 맞춤형 진단 및 치료제를 제공함으로써 맞춤형 의약품 발전을 뒷받침합니다. 예를 들어, 맞춤형 의학 연합(Personalized Medicine Coalition) 보고에 따르면, 2024년 2월 FDA는 희귀질환 환자를 위한 16개의 새로운 맞춤형 치료법을 승인했으며, 이는 2022년 6건 승인 대비 증가한 수치입니다. 이러한 맞춤형 치료법의 급증은 맞춤형 의약품에 대한 관심이 높아지고 있음을 보여주며, 바이오마커 탐색 아웃소싱 서비스에 대한 수요를 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Biomarker discovery outsourcing services refer to specialized services provided by external organizations or companies that assist in identifying, validating, and developing biomarkers. These services play a crucial role in advancing personalized medicine by enabling the identification of biological markers that can guide diagnosis, prognosis, and therapeutic decisions tailored to individual patients.

The main types of biomarker discovery outsourcing services include predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Predictive biomarkers are biological indicators used to identify which patients are likely to benefit from a specific therapeutic intervention. The discovery phases encompass biomarker identification, validation, profiling, panel development, and selection, catering to therapeutic areas such as oncology, cardiology, neurology, autoimmune diseases, and others. End users of these services primarily include pharmaceutical and biotechnology companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The biomarker discovery outsourcing services market research report is one of a series of new reports from The Business Research Company that provides biomarker discovery outsourcing services market statistics, including biomarker discovery outsourcing services industry global market size, regional shares, competitors with an biomarker discovery outsourcing services market share, detailed biomarker discovery outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker discovery outsourcing services industry. This biomarker discovery outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomarker discovery outsourcing services market size has grown rapidly in recent years. It will grow from $14.58 billion in 2024 to $16.96 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increasing disease burden, pharmaceutical R&D demand, the regulatory environment, cost-effective solutions, research collaboration, and globalization.

The biomarker discovery outsourcing services market size is expected to see rapid growth in the next few years. It will grow to $30.13 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to personalized medicine expansion, AI and machine learning integration, precision oncology growth, biomarker validation services, regulatory support, targeted therapy demand, and patient-centric healthcare. Major trends in the forecast period include increased adoption of precision medicine, technological advancements, rising demand for companion diagnostics, expansion of drug development pipelines, emerging applications in non-traditional disease areas, integration of artificial intelligence (AI) and machine learning (ML), regulatory support and standardization, global market expansion, partnerships and collaborations, and a and a focus on cost-effectiveness and time efficiency.

The forecast of 15.4% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. precision medicine by restricting access to proteomic analysis and multi-omics platforms imported from Sweden and Denmark, potentially slowing biomarker identification and increasing research costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing emphasis on personalized medicine is set to drive the growth of the biomarker discovery outsourcing services market. Personalized medicine tailors medical treatment to each patient's individual characteristics, considering genetic, lifestyle, and environmental factors for precise healthcare outcomes and reduced adverse effects. Outsourcing biomarker discovery services supports the advancement of personalized medicine by offering customized diagnostic and therapeutic solutions based on patients' unique biological markers. For example, in February 2024, the FDA approved 16 new personalized treatments for rare disease patients, marking an increase from six approvals in 2022, as reported by the Personalized Medicine Coalition. This surge in personalized treatments highlights the growing focus on personalized medicine, fueling the demand for biomarker discovery outsourcing services.

Leading companies in the biomarker discovery outsourcing services market are concentrating on developing multiplexed biomarker assays, such as the immunoproteomic discovery platform, to enhance patient outcomes and drive advancements in biomarker discovery. The immunoproteomic discovery platform combines immunology and proteomics to identify and analyze proteins linked to the immune response. For instance, Sengenics Corporation LLC launched the immunoproteomic discovery platform in October 2023, offering a comprehensive protein microarray platform for analyzing disease-associated autoantibodies. This platform aids in immune biomarker discovery, supporting research teams in academia and clinical biopharmaceutical sectors to better understand protein interactions and disease dynamics.

In August 2022, Fujirebio Holdings Inc., a Japan-based company specializing in diagnostics, acquired ADx NeuroSciences for $44 million. This acquisition enables Fujirebio to expand its portfolio of in vitro diagnostics and enhance its expertise in biomarker development, with the goal of accelerating innovations in neurological testing. ADx NeuroSciences is a Belgium-based company that specializes in biomarker discovery assays and outsourcing services.

Major companies operating in the biomarker discovery outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC, Crown Bioscience Inc.

North America was the largest region in the biomarker discovery outsourcing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker discovery outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker discovery outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biomarker discovery outsourcing services market includes revenues earned by entities through validation and verification studies, clinical sample analysis, bioinformatics, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker Discovery Outsourcing Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biomarker discovery outsourcing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for biomarker discovery outsourcing services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biomarker discovery outsourcing services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Biomarker Discovery Outsourcing Services Market Characteristics

3. Biomarker Discovery Outsourcing Services Market Trends And Strategies

4. Biomarker Discovery Outsourcing Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Biomarker Discovery Outsourcing Services Growth Analysis And Strategic Analysis Framework

6. Biomarker Discovery Outsourcing Services Market Segmentation

7. Biomarker Discovery Outsourcing Services Market Regional And Country Analysis

8. Asia-Pacific Biomarker Discovery Outsourcing Services Market

9. China Biomarker Discovery Outsourcing Services Market

10. India Biomarker Discovery Outsourcing Services Market

11. Japan Biomarker Discovery Outsourcing Services Market

12. Australia Biomarker Discovery Outsourcing Services Market

13. Indonesia Biomarker Discovery Outsourcing Services Market

14. South Korea Biomarker Discovery Outsourcing Services Market

15. Western Europe Biomarker Discovery Outsourcing Services Market

16. UK Biomarker Discovery Outsourcing Services Market

17. Germany Biomarker Discovery Outsourcing Services Market

18. France Biomarker Discovery Outsourcing Services Market

19. Italy Biomarker Discovery Outsourcing Services Market

20. Spain Biomarker Discovery Outsourcing Services Market

21. Eastern Europe Biomarker Discovery Outsourcing Services Market

22. Russia Biomarker Discovery Outsourcing Services Market

23. North America Biomarker Discovery Outsourcing Services Market

24. USA Biomarker Discovery Outsourcing Services Market

25. Canada Biomarker Discovery Outsourcing Services Market

26. South America Biomarker Discovery Outsourcing Services Market

27. Brazil Biomarker Discovery Outsourcing Services Market

28. Middle East Biomarker Discovery Outsourcing Services Market

29. Africa Biomarker Discovery Outsourcing Services Market

30. Biomarker Discovery Outsourcing Services Market Competitive Landscape And Company Profiles

31. Biomarker Discovery Outsourcing Services Market Other Major And Innovative Companies

32. Global Biomarker Discovery Outsourcing Services Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biomarker Discovery Outsourcing Services Market

34. Recent Developments In The Biomarker Discovery Outsourcing Services Market

35. Biomarker Discovery Outsourcing Services Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기